ARTICLE | Emerging Company Profile
GCTx: Simplifying iPSC-based cell therapy production
Launching with $75M, Cambridge, Mass. start-up aims to shortcut the cell therapy manufacturing process by directly activating transcription factors involved in cell fate
September 19, 2024 1:29 PM UTC
While traditional cell therapy manufacturing involves turning on complex signaling pathways that eventually converge to turn on the right set of transcription factors, GCTx identifies the key transcription factors that determine cell fate and activates them directly.
The company launched Thursday with $75 million, comprising a $10 million seed funding and a $65 million series A round. The series A was led by Bihua Chen’s Cormorant Asset Management, with participation by Mubadala Capital Ventures, Andreessen Horowitz (a16z) Bio + Health, Medical Excellence Capital, Cercano Management and Pear VC...